Condition (MeSH)
Lens Diseases
ClinicalTrials.gov lists 1,464 trials for Lens Diseases or a narrower condition beneath it. Alcon Research has the most among industry and government lead sponsors, with 118.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
18 of the 1,464 trials are tagged with Lens Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Lens Diseases trials start? (36)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 106
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 67 |
| 2025 | 88 |
| 2024 | 87 |
| 2023 | 96 |
| 2022 | 106 |
| 2021 | 97 |
| 2020 | 84 |
| 2019 | 77 |
| 2018 | 87 |
| 2017 | 63 |
Showing 10 of 36 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 87 trials starting in 2026 and about 85 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 28 months from start to primary completion across 89 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 959 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lens Diseases trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 16 |
| Phase 1/2 | 14 |
| Phase 2 | 26 |
| Phase 2/3 | 6 |
| Phase 3 | 90 |
| Phase 4 | 161 |
| Not applicable | 715 |
| Observational | 432 |
| Unknown | 4 |
How many Lens Diseases trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 51 |
| Recruiting | 113 |
| Enrolling by invitation | 12 |
| Active, not recruiting | 38 |
| Completed | 910 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lens Diseases trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alcon Research | 118 |
| Bausch & Lomb Incorporated | 37 |
| Beaver-Visitec International, Inc. | 36 |
| Johnson & Johnson Surgical Vision, Inc. | 26 |
| National Eye Institute (NEI) | 25 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Lens Diseases? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PREDNISOLONE | 15 |
| Bromfenac | 12 |
| Nepafenac | 7 |
| Mapracorat | 5 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cataract surgery | 94 |
| Dexamethasone/Dexamethasone acetate | 17 |
| C: moxifloxacin | 7 |
| Triamcinolone Acetonide alone | 6 |
| Sodium Hyaluronate 1% | 5 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lens Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| hospitalization | 602 | 1 |
| Cardiac Disorders | 428 | 1 |
| Infections and infestations | 394 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 343 | 1 |
| Musculoskeletal and connective tissue disorders | 296 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lens Diseases? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Capsule complication during cataract surgery: Case-control study of preoperative and intraoperative risk factors: Swedish Capsule Rupture Study Group report 2. | Journal of cataract and refractive surgery | 2009 | Yes |
| Late-onset macular degeneration and long anterior lens zonules result from a CTRP5 gene mutation. | Investigative ophthalmology & visual science | 2005 | Yes |
| Phacoemulsification and lens-iris diaphragm retropulsion syndrome. | Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye | 2005 | Yes |
| Anterior chamber depth in eyes with pseudoexfoliation. | The British journal of ophthalmology | 1980 | Yes |
| Vitrectomy for idiopathic epiretinal membranes causing macular pucker. | The British journal of ophthalmology | 1988 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.